Genetic Signatures Ltd
ASX:GSS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.405
0.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GSS stock under the Base Case scenario is 1.31 AUD. Compared to the current market price of 0.7 AUD, Genetic Signatures Ltd is Undervalued by 46%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Genetic Signatures Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GSS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Genetic Signatures Ltd
Balance Sheet Decomposition
Genetic Signatures Ltd
Current Assets | 52.6m |
Cash & Short-Term Investments | 36.3m |
Receivables | 9.6m |
Other Current Assets | 6.7m |
Non-Current Assets | 14.7m |
PP&E | 8.5m |
Intangibles | 6.2m |
Current Liabilities | 5.2m |
Accounts Payable | 3.7m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 950k |
Long-Term Debt | 829k |
Other Non-Current Liabilities | 121k |
Earnings Waterfall
Genetic Signatures Ltd
Revenue
|
14.3m
AUD
|
Cost of Revenue
|
-7.9m
AUD
|
Gross Profit
|
6.4m
AUD
|
Operating Expenses
|
-24.1m
AUD
|
Operating Income
|
-17.7m
AUD
|
Other Expenses
|
-141k
AUD
|
Net Income
|
-17.9m
AUD
|
Free Cash Flow Analysis
Genetic Signatures Ltd
AUD | |
Free Cash Flow | AUD |
GSS Profitability Score
Profitability Due Diligence
Genetic Signatures Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Genetic Signatures Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
GSS Solvency Score
Solvency Due Diligence
Genetic Signatures Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Genetic Signatures Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GSS Price Targets Summary
Genetic Signatures Ltd
According to Wall Street analysts, the average 1-year price target for GSS is 1.12 AUD with a low forecast of 1.11 AUD and a high forecast of 1.16 AUD.
Dividends
Current shareholder yield for GSS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
GSS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
Contact
IPO
Employees
Officers
The intrinsic value of one GSS stock under the Base Case scenario is 1.31 AUD.
Compared to the current market price of 0.7 AUD, Genetic Signatures Ltd is Undervalued by 46%.